In vitro and in vivo evaluation of positively charged liposaccharide derivatives as oral absorption enhancers for the delivery of anionic drugs.
Oral delivery of hydrophilic, ionisable drugs remains a major challenge in drug development and a number of active pharmaceuticals fail to reach the market of oral drugs because of a lack of absorption and/or stability issues. One possible approach to improving the bioavailability of such drug candidates is to increase their lipophilicity, which is a key parameter in the permeation across cell membranes. However, modifying the chemical structure by adding lipid residues often results in changes in activity. With ionised molecules, ion-pairing can be considered to associate charged lipid moieties with the parent drug without altering its structure and therefore activity. This study presents the results of in vitro and in vivo evaluation of a series of synthetic, positively charged liposaccharide derivatives combined with an anionic model drug, piperacillin. The antimicrobial activity, plasma stability, Caco-2 cell permeability and oral absorption of the conjugates were assessed. Increases in apparent permeability were observed in vitro for three of the tested formulations, while retaining the antibacterial activity of the drug. However, the in vivo intestinal absorption of piperacillin formulated with the liposaccharide derivatives was found unchanged, possibly due to molecular dissociation, early degradation or structural differences between the intestinal epithelium and cultured monolayers.
Bergeon
Julie A
JA
School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, Qld 4072, Australia. j.bergeon@uq.edu.au
Ziora
Zyta M
ZM
Abdelrahim
Adel S
AS
Pernevi
Niklas U
NU
Moss
Anne R
AR
Toth
Istvan
I
D000042:Absorption; D000284:Administration, Oral; D000818:Animals; D000838:Anions / Q000008:administration & dosage / Q000737:chemistry; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology; D018938:Caco-2 Cells; D002151:Calorimetry; D018929:Cell Culture Techniques; D004337:Drug Carriers / Q000737:chemistry* / Q000494:pharmacology; D004355:Drug Stability; D004912:Erythrocytes / Q000187:drug effects; D004926:Escherichia coli / Q000187:drug effects; D006461:Hemolysis / Q000187:drug effects; D006801:Humans; D008070:Lipopolysaccharides / Q000737:chemistry* / Q000494:pharmacology; D008297:Male; D008826:Microbial Sensitivity Tests; D015394:Molecular Structure; D009061:Mouth Mucosa / Q000187:drug effects / Q000378:metabolism*; D010539:Permeability; D004364:Pharmaceutical Preparations / Q000008:administration & dosage* / Q000737:chemistry; D010878:Piperacillin / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D051381:Rats; D017207:Rats, Sprague-Dawley; D021241:Spectrometry, Mass, Electrospray Ionization; D055672:Static Electricity; D053719:Tandem Mass Spectrometry
D000838:Anions; D000900:Anti-Bacterial Agents; D004337:Drug Carriers; D008070:Lipopolysaccharides; D004364:Pharmaceutical Preparations; D010878:Piperacillin